AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% FDC 3.33 ▼-1.19% KOA 3.10 ▲1.64% AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% FDC 3.33 ▼-1.19% KOA 3.10 ▲1.64%

CSL CSL Limited

Healthcare · Biotechnology · website · 29,904 employees
$124.30
52wk 90.00 – 273.45
Overall
Value
Growth
Health
Quality
Momentum
Dividend
Price
About CSL Limited

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$59.53B
P/E (trailing)
14.01
P/E (forward)
13.78
EPS (trailing)
8.87
Dividend yield
3.4%
Payout ratio
45.5%
Beta
0.09
EV / EBITDA
14.70
Price / Book
2.25
ROE
6.7%
Operating margin
31.6%
Net margin
9.1%
Total cash
$1.14B
Total debt
$11.14B
Current ratio
2.57
Debt / Equity
0.54
Free cash flow
$1.85B
Avg volume
1.84M
Latest annual results (FY ending 30 Jun 2025)
  • Revenue$15.43B
  • Gross profit$7.95B
  • Operating income$2.96B
  • Net income$3.00B
  • Diluted EPS6.17
  • Free cash flow$2.54B
  • Net debt$9.34B
Sector peers (Healthcare)
TickerMkt cap P/EScore
RMD $43.89B 20.4
SIG $34.28B 59.4
FPH $20.25B 52.2
PME $17.21B 73.5
SHL $10.79B 19.7
RHC $10.13B 34.8
COH $7.90B 22.9
ANN $4.69B 24.8